

Special Issue

Vaccine Adjuvants Research

Message from the Guest Editor

The appearance of the SARS-CoV-2 virus in 2020 brings, again, to public discussion, the importance of being prepared for the development of vaccines in a short period of time. Reverse vaccinology and proteomic approaches have allowed rapid identification of the antigenic structures and, thus, the design of a successful vaccine. A huge diversity of vaccines is being tested, based on RNA, DNA, recombinant proteins, inactivated and attenuated virus, and viral vectors. Appropriate adjuvants for these vaccines are not approved and need to be developed not only for injectable vaccines but, also, to obtain more stable, needle-free, oral, and intranasal vaccines. These last modalities would help to not only increase the vaccine coverage but also more rapidly, and to decrease the infections associated with bad clinical practice during the administration of injectables, especially in developing countries. The objective of this Special Issue of *Vaccines* is to cover the most recent developments in vaccine adjuvants and formulations.

Guest Editor

Prof. Dr. Olga Borges

Center for Neurosciences and Cell Biology (CNC), Faculty of Pharmacy,
University of Coimbra, Coimbra, Portugal

Deadline for manuscript submissions

closed (31 July 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/71975

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).